Randomized Withdrawal Study in Patients With Schizophrenia
Start Date
5/14/2025
Completion Date
11/1/2027
Summary
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
Eligibility Criteria
Age Range: 18 years to 65 years
Interventions
iloperidone
placebo
Conditions
Locations
Vanda Investigational Site
Rogers, Arkansas 72758
United States
Vanda Investigational Site
Costa Mesa, California 92626
United States
Vanda Investigational Site
Lemon Grove, California 91945
United States
Vanda Investigational Site
Oceanside, California 92056
United States
Vanda Investigational Site
Pico Rivera, California 90660
United States
Vanda Investigational Site
San Diego, California 92123
United States
Vanda Investigational Site
Walnut Creek, California 94596
United States
Vanda Investigational Site
North Miami, Florida 33161
United States
Vanda Investigational Site
Atlanta, Georgia 30328
United States
Vanda Investigational Site
Peachtree Corners, Georgia 30071
United States
Vanda Investigational Site
Chicago, Illinois 60641
United States
Vanda Investigational Site
Flowood, Mississippi 39232
United States
Vanda Investigational Site
Saint Charles, Missouri 63304
United States
Vanda Investigational Site
St Louis, Missouri 63141
United States
Vanda Investigational Site
Las Vegas, Nevada 89119
United States
Vanda Investigational Site
Marlton, New Jersey 08053
United States
Vanda Investigational Site
Staten Island, New York 10314
United States
Vanda Investigational Site
Austin, Texas 78754
United States
Vanda Investigational Site
Houston, Texas 77081
United States
Vanda Investigational Site
Irving, Texas 75062
United States
Vanda Investigational Site
Richardson, Texas 75080
United States
Vanda Investigational Site
Bellevue, Washington 98007
United States